Gonzalez-Rellan, Maria J. http://orcid.org/0000-0001-8986-9244
Fondevila, Marcos F. http://orcid.org/0000-0002-5099-3421
Fernandez, Uxia http://orcid.org/0000-0001-9728-2590
Rodríguez, Amaia http://orcid.org/0000-0002-2180-461X
Varela-Rey, Marta
Veyrat-Durebex, Christelle http://orcid.org/0000-0001-5301-6493
Seoane, Samuel
Bernardo, Ganeko http://orcid.org/0000-0002-1372-3844
Lopitz-Otsoa, Fernando http://orcid.org/0000-0001-8452-6939
Fernández-Ramos, David
Bilbao, Jon
Iglesias, Cristina
Novoa, Eva
Ameneiro, Cristina
Senra, Ana
Beiroa, Daniel
Cuñarro, Juan
DP Chantada-Vazquez, Maria
Garcia-Vence, Maria
Bravo, Susana B.
Da Silva Lima, Natalia
Porteiro, Begoña
Carneiro, Carmen
Vidal, Anxo
Tovar, Sulay http://orcid.org/0000-0001-7813-6520
Müller, Timo D.
Ferno, Johan
Guallar, Diana http://orcid.org/0000-0001-5834-7507
Fidalgo, Miguel http://orcid.org/0000-0003-1134-2674
Sabio, Guadalupe
Herzig, Stephan http://orcid.org/0000-0003-3950-3652
Yang, Won Ho
Cho, Jin Won
Martinez-Chantar, Maria Luz http://orcid.org/0000-0002-6446-9911
Perez-Fernandez, Roman http://orcid.org/0000-0002-5894-0615
López, Miguel http://orcid.org/0000-0002-7823-1648
Dieguez, Carlos
Mato, Jose M. http://orcid.org/0000-0003-1264-3153
Millet, Oscar
Coppari, Roberto
Woodhoo, Ashwin http://orcid.org/0000-0002-8395-2837
Fruhbeck, Gema http://orcid.org/0000-0002-8305-7154
Nogueiras, Ruben http://orcid.org/0000-0002-9976-9930
Article History
Received: 26 June 2020
Accepted: 6 August 2021
First Online: 20 August 2021
Competing interests
: The authors declare the following competing interests: O.M. and G.B. are employees of ATLAS Molecular Pharma.